Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients

Launched by TEL-AVIV SOURASKY MEDICAL CENTER · Mar 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how patients with multiple myeloma, a type of blood cancer, respond to new treatments called bispecific antibodies and CAR-T therapies. The goal is to understand why some patients do well with these treatments while others do not. Researchers will collect blood and bone marrow samples from up to 200 patients aged 18 and older who are eligible for these therapies. They will look at the genetic and protein changes in the cancer cells and their environment to help find better, personalized treatment options for multiple myeloma in the future.

To participate, patients must be diagnosed with multiple myeloma and be candidates for the new therapies being tested. They should also be mentally competent to provide consent to join the study. Participants can expect to have their blood and bone marrow samples collected before starting treatment and at different times afterward, including if their disease worsens. The study is not yet recruiting, and it will take several years to collect and analyze the results, but the findings could significantly improve how multiple myeloma is treated.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed with multiple myeloma Candidate for BisAb, CAR-T, or other myeloma therapy Mentally competent and able to sign informed consent
• Exclusion Criteria:
• • Unable to undergo bone marrow sampling Pregnant women Minors (\<18), incapacitated, or legally incompetent